Cargando…
Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
Bevacizumab is used to treat glioblastoma; however, no current biomarker predicts its efficacy. We used an exploratory cohort of patients treated with the radiochemotherapy then bevacizumab or chemotherapy at recurrence (N = 265). Bevacizumab use increased median overall survival (OS) 18.7 vs 11.3 m...
Autores principales: | Bertaut, Aurélie, Truntzer, Caroline, Madkouri, Rachid, Kaderbhai, Coureche Guillaume, Derangère, Valentin, Vincent, Julie, Chauffert, Bruno, Aubriot-Lorton, Marie Hélene, Farah, Wahlid, Mourier, Klaus Luc, Boidot, Romain, Ghiringhelli, Francois |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342600/ https://www.ncbi.nlm.nih.gov/pubmed/27487142 http://dx.doi.org/10.18632/oncotarget.10898 |
Ejemplares similares
-
Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type
por: Dalens, Lorraine, et al.
Publicado: (2023) -
Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
por: Ballot, Elise, et al.
Publicado: (2022) -
MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
por: Lecuelle, Julie, et al.
Publicado: (2022) -
Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort
por: Tankere, Pierre, et al.
Publicado: (2022) -
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing
por: Galland, Loïck, et al.
Publicado: (2022)